ENTX - Entera Bio Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7000
-0.2700 (-6.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.9700
Open3.9000
Bid3.88 x 900
Ask4.25 x 1300
Day's Range3.6100 - 4.0808
52 Week Range2.5500 - 7.6000
Volume72,655
Avg. Volume13,709
Market Cap42.285M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Entera Bio Appoints Gerald M. Ostrov to Board of Directors

    JERUSALEM, Jan. 10, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors,.

  • MarketWatchlast month

    Entera shares jump 11.5% on news of collaboration with Amgen

    Shares of Entera Bio Ltd. and Amgen Inc. rose Tuesday, after they announced a research collaboration in inflammatory disease and other serious illnesses. As part of the deal, Entera will use its proprietary drug delivery platform to develop oral versions of one preclinical large molecule program selected by Amgen. Amgen has the option of selecting two other programs to add to the collaboration. Entera will be eligible to receive up to $270 million in aggregate payments, along with tiered royalties up to mid-single digits upon reaching various milestones. It will retain IP rights to its technology. Entera shares rose 11.5% in early trade and are up 23% in the last three months, while the S&P 500 has fallen 7.7%. Amgen shares were up about 1%.

  • GlobeNewswirelast month

    Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

    Entera Bio Ltd. (ENTX) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.

  • GlobeNewswire2 months ago

    Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

    Entera Bio Ltd. (ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [“Oral PTH (1-34)”]. “The results from Part 1 of the PK/PD study in patients with hypoparathyroidism have confirmed that Oral PTH (1-34) activates biological pathways that PTH is known to regulate.